Unlocking the True Value of Multiplexing IHC – From Clinical Trial Programs Through to IVD Applications

This webinar ran on Tuesday March 30, 2021 | 8am PST | 11am EST

Webinar Hosted by
Abcam

Abcam-Logo.cropped

The March Abcam Webinar Covered:

Unlocking the True Value of Multiplexing IHC – From Clinical Trial Programs Through to IVD Applications

This exclusive webinar provided leaders in pharma and biotech with an opportunity to explore the potential and the long-term aspirations of mIHC for clinical trials and IVD applications.

Providing perspectives from leading experts in the field, attendees gained the latest insights on how to overcome the challenges of getting mIHC ready for IVD use and discussed how to successfully incorporate and speed up the use of mIHC in their clinical trial settings.

WEBINAR PRESENTERS

Angela Vasaturo

Associate Director Biomarker Strategy and Applications

Ultivue

Keith Wharton

VP Medical Director

Ultivue

Oliver Stoss

Chief Executive Officer

Targos Inc.

Will Howat

Senior Director of Antibody Validation & Characterization

Abcam

KEY OBJECTIVES

  • Realizing the potential of using mIHC for clinical trials and how to overcome the challenges of getting it ready for IVD use
  • Discovering the value of the right antibody content to warrant mIHC and the importance of the reagent and panel validation
  • Strategizing for long-term aspirations: Understanding how pharma can be supported with content, assay development and assay deployment to speed up use of mIHC in clinical trial settings and how to work towards a successful global deployment and seamless incorporation of this technology into your process for robust and reproducible large-scale adoption

WHO SHOULD ATTEND

This is an event for executives from Immuno-Oncology, Oncology, & Neuroscience departments of biopharmas looking to understand how pharma is currently employing mIHC and its benefits and applications in clinical settings. This exclusive digital event will bring perspectives from leading experts to get an overview of how to rapidly advance the key stages of an mIHC from analytical validation to demonstration of clinical utility, all the way through to IVD applications.

ABOUT ABCAM

Abcam-Logo.cropped

Accelerate your next breakthrough in diagnostics and therapeutics. Abcam’s comprehensive portfolio of high quality, customizable solutions are ideal for diagnostic and therapeutic applications. Our technical ability coupled with a flexible commercial approach enables us to deliver projects that will help achieve your goals.

www.abcam.com